Investigating a new treatment for cognitive impairment in Alzheimer's disease.
IND Enabling Studies for RASRx 1902, a novel Mas receptor agonist, for treatment of cognitive impairment in patients at risk for Alzheimer's disease.
This study is testing a new pill called RASRx 1902 to see if it can help improve thinking and memory for people at risk of Alzheimer's by reducing inflammation and stress in the brain.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-10644987 on NIH RePORTER |
What this research studies
This research focuses on developing a novel medication, RASRx 1902, which targets the Mas receptor to help treat cognitive impairment in individuals at risk for Alzheimer's disease. The approach involves understanding how this medication can reduce inflammation and oxidative stress, which are believed to contribute to the progression of Alzheimer's. By using small molecule analogues of a naturally occurring peptide, the research aims to create a more effective treatment option that can be taken orally. Patients participating in this research may receive this new treatment as part of the clinical trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults who are at risk for developing Alzheimer's disease, particularly those with cognitive impairment.
Not a fit: Patients who are not at risk for Alzheimer's disease or do not exhibit cognitive impairment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new therapeutic option that may slow down or improve cognitive decline in patients at risk for Alzheimer's disease.
How similar studies have performed: Previous studies have shown promising results with similar approaches targeting the Renin Angiotensin System in Alzheimer's models, indicating potential for success in this novel treatment.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Rodgers, Kathleen E. — University of Arizona
- Study coordinator: Rodgers, Kathleen E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.